FATE THERAPEUTICS INC (FATE) Stock Fundamental Analysis

NASDAQ:FATE • US31189P1021

1.25 USD
+0.05 (+4.17%)
At close: Feb 13, 2026
1.2738 USD
+0.02 (+1.9%)
After Hours: 2/13/2026, 8:06:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall FATE gets a fundamental rating of 3 out of 10. We evaluated FATE against 523 industry peers in the Biotechnology industry. FATE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FATE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year FATE has reported negative net income.
  • In the past year FATE has reported a negative cash flow from operations.
  • In the past 5 years FATE always reported negative net income.
  • FATE had a negative operating cash flow in each of the past 5 years.
FATE Yearly Net Income VS EBIT VS OCF VS FCFFATE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • FATE has a Return On Assets of -45.42%. This is comparable to the rest of the industry: FATE outperforms 53.73% of its industry peers.
  • The Return On Equity of FATE (-66.69%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -45.42%
ROE -66.69%
ROIC N/A
ROA(3y)-37.99%
ROA(5y)-32.97%
ROE(3y)-53.45%
ROE(5y)-47.34%
ROIC(3y)N/A
ROIC(5y)N/A
FATE Yearly ROA, ROE, ROICFATE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

  • FATE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FATE Yearly Profit, Operating, Gross MarginsFATE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • FATE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for FATE has been increased compared to 1 year ago.
  • The number of shares outstanding for FATE has been increased compared to 5 years ago.
  • There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FATE Yearly Shares OutstandingFATE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
FATE Yearly Total Debt VS Total AssetsFATE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -6.20, we must say that FATE is in the distress zone and has some risk of bankruptcy.
  • FATE's Altman-Z score of -6.20 is on the low side compared to the rest of the industry. FATE is outperformed by 63.29% of its industry peers.
  • There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.2
ROIC/WACCN/A
WACC12.25%
FATE Yearly LT Debt VS Equity VS FCFFATE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 7.87 indicates that FATE has no problem at all paying its short term obligations.
  • FATE's Current ratio of 7.87 is fine compared to the rest of the industry. FATE outperforms 73.81% of its industry peers.
  • A Quick Ratio of 7.87 indicates that FATE has no problem at all paying its short term obligations.
  • FATE has a better Quick ratio (7.87) than 73.81% of its industry peers.
Industry RankSector Rank
Current Ratio 7.87
Quick Ratio 7.87
FATE Yearly Current Assets VS Current LiabilitesFATE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 20.00% over the past year.
  • The Revenue for FATE has decreased by -46.92% in the past year. This is quite bad
  • Measured over the past years, FATE shows a small growth in Revenue. The Revenue has been growing by 5.00% on average per year.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.5%
Revenue 1Y (TTM)-46.92%
Revenue growth 3Y-37.51%
Revenue growth 5Y5%
Sales Q2Q%-43.36%

3.2 Future

  • FATE is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.39% yearly.
  • FATE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.35% yearly.
EPS Next Y28.57%
EPS Next 2Y13.41%
EPS Next 3Y10.23%
EPS Next 5Y5.39%
Revenue Next Year-52.5%
Revenue Next 2Y-40.53%
Revenue Next 3Y-42.56%
Revenue Next 5Y36.35%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FATE Yearly Revenue VS EstimatesFATE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
FATE Yearly EPS VS EstimatesFATE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • FATE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FATE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FATE Price Earnings VS Forward Price EarningsFATE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FATE Per share dataFATE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.41%
EPS Next 3Y10.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for FATE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FATE THERAPEUTICS INC

NASDAQ:FATE (2/13/2026, 8:06:06 PM)

After market: 1.2738 +0.02 (+1.9%)

1.25

+0.05 (+4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-02
Inst Owners79.44%
Inst Owner Change-0.18%
Ins Owners1.04%
Ins Owner Change4.34%
Market Cap144.19M
Revenue(TTM)7.14M
Net Income(TTM)-156.09M
Analysts77.78
Price Target5.04 (303.2%)
Short Float %10.07%
Short Ratio7.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.02%
Min EPS beat(2)9.06%
Max EPS beat(2)16.98%
EPS beat(4)4
Avg EPS beat(4)11.09%
Min EPS beat(4)0.25%
Max EPS beat(4)18.09%
EPS beat(8)8
Avg EPS beat(8)13.36%
EPS beat(12)12
Avg EPS beat(12)20.15%
EPS beat(16)15
Avg EPS beat(16)16.29%
Revenue beat(2)2
Avg Revenue beat(2)48.07%
Min Revenue beat(2)11.18%
Max Revenue beat(2)84.97%
Revenue beat(4)4
Avg Revenue beat(4)41.19%
Min Revenue beat(4)11.18%
Max Revenue beat(4)84.97%
Revenue beat(8)8
Avg Revenue beat(8)91.97%
Revenue beat(12)11
Avg Revenue beat(12)82.36%
Revenue beat(16)14
Avg Revenue beat(16)73.22%
PT rev (1m)0%
PT rev (3m)6.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.92%
EPS NY rev (1m)0%
EPS NY rev (3m)1.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-32.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.2
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-1.32
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.06
BVpS2.03
TBVpS2.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.42%
ROE -66.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.99%
ROA(5y)-32.97%
ROE(3y)-53.45%
ROE(5y)-47.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.17%
Cap/Sales 68.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.87
Quick Ratio 7.87
Altman-Z -6.2
F-Score2
WACC12.25%
ROIC/WACCN/A
Cap/Depr(3y)98.67%
Cap/Depr(5y)264.44%
Cap/Sales(3y)17.33%
Cap/Sales(5y)31.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.5%
EPS Next Y28.57%
EPS Next 2Y13.41%
EPS Next 3Y10.23%
EPS Next 5Y5.39%
Revenue 1Y (TTM)-46.92%
Revenue growth 3Y-37.51%
Revenue growth 5Y5%
Sales Q2Q%-43.36%
Revenue Next Year-52.5%
Revenue Next 2Y-40.53%
Revenue Next 3Y-42.56%
Revenue Next 5Y36.35%
EBIT growth 1Y18.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.06%
EBIT Next 3Y1.67%
EBIT Next 5YN/A
FCF growth 1Y37.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.35%
OCF growth 3YN/A
OCF growth 5YN/A

FATE THERAPEUTICS INC / FATE FAQ

Can you provide the ChartMill fundamental rating for FATE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to FATE.


Can you provide the valuation status for FATE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FATE THERAPEUTICS INC (FATE). This can be considered as Overvalued.


What is the profitability of FATE stock?

FATE THERAPEUTICS INC (FATE) has a profitability rating of 1 / 10.